Zevra Therapeutics Inc (ZVRA)
4.73
-0.03
(-0.63%)
USD |
NASDAQ |
May 17, 16:00
4.73
0.00 (0.00%)
After-Hours: 20:00
Zevra Therapeutics Cash from Financing (Quarterly): 1.217M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 1.217M |
| December 31, 2023 | 5.004M |
| September 30, 2023 | 26.26M |
| June 30, 2023 | 0.951M |
| March 31, 2023 | -3.75M |
| December 31, 2022 | -0.257M |
| September 30, 2022 | -0.409M |
| June 30, 2022 | 13.75M |
| March 31, 2022 | -4.733M |
| December 31, 2021 | -2.87M |
| September 30, 2021 | 1.942M |
| June 30, 2021 | 39.75M |
| March 31, 2021 | 74.29M |
| December 31, 2020 | -0.046M |
| September 30, 2020 | -0.051M |
| June 30, 2020 | 1.816M |
| March 31, 2020 | 1.02M |
| December 31, 2019 | -0.35M |
| September 30, 2019 | 1.443M |
| June 30, 2019 | 1.176M |
| March 31, 2019 | 2.67M |
| Date | Value |
|---|---|
| December 31, 2018 | 23.26M |
| September 30, 2018 | 0.788M |
| June 30, 2018 | 1.217M |
| March 31, 2018 | 2.749M |
| December 31, 2017 | -0.038M |
| September 30, 2017 | -0.042M |
| June 30, 2017 | -0.06M |
| March 31, 2017 | -0.063M |
| December 31, 2016 | -0.463M |
| September 30, 2016 | -2.006M |
| June 30, 2016 | 0.02M |
| March 31, 2016 | 63.61M |
| December 31, 2015 | -1.246M |
| September 30, 2015 | -0.548M |
| June 30, 2015 | 59.23M |
| March 31, 2015 | 4.034M |
| December 31, 2014 | -1.774M |
| September 30, 2014 | -0.041M |
| June 30, 2014 | 24.84M |
| March 31, 2014 | -0.022M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-4.733M
Minimum
Mar 2022
74.29M
Maximum
Mar 2021
7.808M
Average
1.098M
Median
Cash from Financing (Quarterly) Benchmarks
| Perspective Therapeutics Inc | 166.33M |
| Dare Bioscience Inc | 0.014M |
| OptiNose Inc | 0.007M |
| Kodiak Sciences Inc | 0.038M |
| INmune Bio Inc | -2.50M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -16.16M |
| Cash from Investing (Quarterly) | 14.79M |
| Free Cash Flow | -45.66M |
| Free Cash Flow Per Share (Quarterly) | -0.3869 |
| Free Cash Flow to Equity (Quarterly) | -16.40M |
| Free Cash Flow to Firm (Quarterly) | -16.16M |
| Free Cash Flow Yield | -25.41% |